Access cutting-edge relapsed and/or refractory multiple myeloma (rrmm) treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New York location
Preparing your pre-screening questions…
Access relapsed and/or refractory multiple myeloma (rrmm) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related relapsed and/or refractory multiple myeloma (rrmm) treatment provided free
Check if you qualify for this relapsed and/or refractory multiple myeloma (rrmm) clinical trial in New York, NY
No-Cost Study Care
Local to New York
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Sponsor: Regeneron Pharmaceuticals
Yes, this clinical trial (NCT07222761) has an active research site in New York, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for relapsed and/or refractory multiple myeloma (rrmm) treatment options in New York, NY, this clinical trial (NCT07222761) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed and/or refractory multiple myeloma (rrmm) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all relapsed and/or refractory multiple myeloma (rrmm) clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in New York — not just this study.
Browse Multiple Myeloma Trials in New York →